Seeing Is Believing
Currently out of the existing stock ratings of Kemp Dolliver, 7 are a BUY (77.78%), 2 are a HOLD (22.22%).
Analyst Kemp Dolliver, currently employed at BROOKLINE, carries an average stock price target met ratio of 16.67% that have a potential upside of 7.42% achieved within 12 days.
Kemp Dolliver’s has documented 17 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on DARE, Dare Bioscience at 15-May-2024.
Analyst best performing recommendations are on DARE (DARE BIOSCIENCE).
The best stock recommendation documented was for DARE (DARE BIOSCIENCE) at 9/5/2023. The price target of $5 was fulfilled within 51 days with a profit of $2.92 (36.87%) receiving and performance score of 7.23.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$15
$3.79 (33.81%)
$11
10 months 1 days ago
(22-Jan-2024)
5/7 (71.43%)
$7.77 (107.47%)
439
Buy
$1.25
$-5.56 (-81.64%)
1 years 10 months 10 days ago
(13-Jan-2023)
0/1 (0%)
$-3.28 (-72.41%)
What Year was the first public recommendation made by Kemp Dolliver?